Miniaturized Synthesis Technology for TERACARRIER based Radiopharmaceuticals. Enabling rapid field deployment of drug manufacturing through miniaturization & automation of the producer machine.
Zhyper-X® is a fully automated TERACARRIER based Radiopharmaceutical synthesizer that can cover the entire process of synthesis-refinement-formulation-QC/QA-Packaging. The auto-system can produce a ready-to-go radioisotope drug within 24hours. The miniaturization simplifies the manufacturing establishment allowing the field deployment of the synthesis device. Thus, Zhyper-X® can solve, not only the short half-life issue, but also remove the necessity of initial asset investment and time to set up facilities for radiopharmaceutical manufacturing through the fast deployment of miniaturized devices. ZTI BIOSCIENCES sets the next standard for the production & logistics of Radiopharmaceuticals.
ZTI’s Radiopharmaceuticals can be administered within 24 hours from production with the technology enabling the field synthesis near hospitals by miniaturization & automation of the drug producer machine. ZTI’s Radiopharmaceutical Synthesis Technology will bring the best solution to the short half-life of nuclear medicine.
With ZTI’s cold-type drug & radioisotopes ready supplied, the Zhyper-X can produce and purify to produce ready-to-go radiopharmaceuticals within 24hours. This will allow us access to the best to the counter strategy against the short half-life issue of radioisotope therapy.
With Zhyper-X installed near designated hospitals, we can remove the lead time that is spent with facility manufacturing + packaging + delivery.
In conventional Radiopharmaceuticals’ logistics, the Delivery alone, after manufacturing and packaging is done, is expected to take at least 3-4days minimum. But with the field synthesis technology available, we can directly ship the isotopes to the Zhyper-X installed sites to have the radioisotopes ready in 24 hours. Just have the drug carriers ready and isotopes delivered a day before, by the time the patient arrives for the administration, the nuclear medicine will have 90% of it’s efficacy still intact.